Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer

by Robert Bazell

Book Overview

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.

Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of...

• Format: Paperback
• Language: English
• ISBN: 0812991842
• ISBN13: 9780812991840
• Release Date: August 1998
• Publisher: Random House Publishing Group
• Length: 240 Pages
• Weight: 0.80 lbs.
• Dimensions: 0.6" x 6.1" x 9.0"

Customer Reviews

Good to the Last Page

I had to read this book for my Biotechnology class and although I am close to failing it I found Her-2 to be pretty exciting book.Her-2 by Bazell and King is about breast cancer, however, it reveals many other interesting things about the drug industry and how progress is made in the medical research field. There are different stories and view points and the authors have succesfully managed to combine all this into a book that both teaches and thrills us. I recommend this book to everyone who wants to learn more about breast cancer and about the insights of creating and bringing to the market a revolutionary drug - from selection of the trial patients to the President's office.

A Her-2 Victim's Review

I cried and rejoiced all through this book, which I finished today. I knew very little about my condition, which is Her2neu +3 positivity, the highest level of Her2, until I read it. My first oncologist wanted to keep me in the dark, and if it weren't for folks like Mr. Bazzell, I would still be in the dark. I now have the ammunition I need to be more active in my treatment options. I also am so thankful to read about the discovery of this oncogene, and cannot express adequately enough my gratitude to one of the main subjects of this book, Dennis Salmon, for his dedication to the discovery of Her2 and all he has done to get the drug, Herceptin on the market. Anyone who overexpresses Her2neu must have this book. This breast cancer is phenomenally deadly, and more able to recur and can spread like wildfire, even during chemotherapy and radiation, so thank goodness now I know, from reading this, what can happen, and what needs to be done.

A must read for anyone fighting breast cancer

I wish I had read this book last year. I ordered while my sister was being treated with Herceptin for a recurrence of breast cancer. Unfortunately, she died before I could get the book. This book give real insight into the politics of cancer treatment - the passiveness of some oncologists, how an executive's own personal experience with a disease can determine if drug development will go forward or not, and how women are becoming more aggressive in monitoring their own treatment. Bazell talks about the frustrations of critically ill and dying women in trying to work through the medical, academic and managed care maze to get the treatment they need. This drug has been the 'magic bullet' for many women. It has been called the start of a new era is disease treatment. It is essential for anyone involved in this disease to read this book, to understand what they are up against and how they can help themselves.

A must read for husbands.

My wife has been recieving weekly doses of Herceptin for a year now. A facinating story of how this miracle drug came to be.Reading about how Herceptin grew from a theory to reality, how the marketplace influenced development and the personalities of the people involved made this a real page turner, I couldn't put it down!

For Thinking Women and Scientists Alike

This is the thinking woman's cancer book. If you are a science buff, cancer pioneer or a woman who wants to know what really happens in the world of science and drug revolutions, read this book.It's well written, bitter-sweet and manages to be simulataneously scientific and humanistic.